Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Комплексное лечение больного с диабетической полинейропатией
Комплексное лечение больного с диабетической полинейропатией
Камчатнов П.Р., Евзельман М.А. Комплексное лечение больного с диабетической полинейропатией. Consilium Medicum. 2016; 18 (2): 81–84. DOI: 10.26442/2075-1753_2016.2.81-84
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Сахарный диабет – распространенное заболевание, одним из осложнений которого становится диабетическая полинейропатия (ДПН). ДПН проявляется двигательными и чувствительными нарушениями, причем именно нейропатический болевой синдром становится важной причиной снижения качества жизни больных. Поражение вегетативной нервной системы в рамках ДПН ассоциировано с риском жизнеугрожающих состояний (инсульт, тяжелые нарушения ритма сердца) и наступлением летального исхода. Рассматриваются возможности применения препарата тиоктовой кислоты (Октолипен®) в качестве средства патогенетической терапии ДПН. Приведены данные об эффективности габапентина (Конвалис®) для купирования болевого синдрома при ДПН.
Ключевые слова: сахарный диабет, диабетическая полинейропатия, вегетативная полинейропатия, тиоктовая кислота, габапентин, Октолипен, Конвалис.
Key words: diabetes mellitus, diabetic neuropathy, autonomic neuropathy, tioctic acid, gabapentin, Octopilen, Convalis.
Ключевые слова: сахарный диабет, диабетическая полинейропатия, вегетативная полинейропатия, тиоктовая кислота, габапентин, Октолипен, Конвалис.
________________________________________________
Key words: diabetes mellitus, diabetic neuropathy, autonomic neuropathy, tioctic acid, gabapentin, Octopilen, Convalis.
Полный текст
Список литературы
1. Vincent A, Calabek B, Roberts L, Feldman E. Biology of diabetic neuropathy. Handb Clin Neurol 2013; 115: 591–606.
2. Head KA. Peripheral Neuropathy: Pathogenic Mechanisms and Alternative Therapies. Alternative Med Rev 2006; 11: 294–300.
3. Witzel I-I, Jelinek H, Khalaf K et al. Identifying Common Genetic Risk Factors of Diabetic Neuropathies. Front Endocrinol (Lausanne) 2015; 6: 88–93.
4. Jin HY, Baek HS, Park TS. Morphologic Changes in Autonomic Nerves in Diabetic Autonomic Neuropathy. Diabetes Metab J 2015; 39(6): 461–7.
5. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029–52.
6. Koo BK. Screening of autonomic neuropathy in patients with type 2 diabetes. Diabetes Metab J 2014; 38: 346–8.
7. Гурьева И.В., Левин О.С. Диабетическая полинейропатия. Consilium Medicum. 2014; 16 (4): 12–6. / Gur'eva I.V., Levin O.S. Diabeticheskaia polineiropatiia. Consilium Medicum. 2014; 16 (4): 12–6. [in Russian]
8. Karayannis G, Giamouzis G, Cokkinos D et al. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 2012; 10 (6): 747–65.
9. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne) 2014; 5: 205–10.
10. Cohena J, Estaciob R, Lundgrenc R et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108 (1–2): 7–8.
11. Sun L, Chen Y, Wang X et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol 2012; 84 (7): 961–73.
12. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
13. Mitkov M, Aleksandrova I, Orbetzova M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55 (1): 55–63.
14. Tesfaye S, Boulton A, Dickenson A. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36 (9): 2456–65.
15. Snedecor S, Sudharshan L, Cappelleri J et al. Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. Pain Pract 2014; 14 (2): 167–84.
16. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167 (4): 465–71.
17. Maizels M, Mccarberg B. Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain. J Am Ac Fam Physicians 2005; 71; 3: 188–192.
18. Taylor C. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153 (Suppl. 1): S39–45.
19. Backonja M, Beydoun A, Edwards K et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6.
20. Rowbotham M, Harden N, Stacey B, Bernstein P. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42.
21. Hempenstall K, Nurmikko T, Johnson R et al. Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review. PLoS Med 2005; 2 (7): 164–9.
22. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. The Cochrane Database of Syst Rev 2005; 3. Art. No.: CD005452.
23. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16 (2 Suppl.): S67–72.
24. Morello C., Leckband S., Stoner C. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159 (16): 1931–7.
25. Dworkin R, O'Connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl.): S3–14.
26. Храмилин В.Н., Андреева В.Л., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16.
2. Head KA. Peripheral Neuropathy: Pathogenic Mechanisms and Alternative Therapies. Alternative Med Rev 2006; 11: 294–300.
3. Witzel I-I, Jelinek H, Khalaf K et al. Identifying Common Genetic Risk Factors of Diabetic Neuropathies. Front Endocrinol (Lausanne) 2015; 6: 88–93.
4. Jin HY, Baek HS, Park TS. Morphologic Changes in Autonomic Nerves in Diabetic Autonomic Neuropathy. Diabetes Metab J 2015; 39(6): 461–7.
5. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029–52.
6. Koo BK. Screening of autonomic neuropathy in patients with type 2 diabetes. Diabetes Metab J 2014; 38: 346–8.
7. Gur'eva I.V., Levin O.S. Diabeticheskaia polineiropatiia. Consilium Medicum. 2014; 16 (4): 12–6. [in Russian]
8. Karayannis G, Giamouzis G, Cokkinos D et al. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 2012; 10 (6): 747–65.
9. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne) 2014; 5: 205–10.
10. Cohena J, Estaciob R, Lundgrenc R et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108 (1–2): 7–8.
11. Sun L, Chen Y, Wang X et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol 2012; 84 (7): 961–73.
12. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
13. Mitkov M, Aleksandrova I, Orbetzova M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55 (1): 55–63.
14. Tesfaye S, Boulton A, Dickenson A. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36 (9): 2456–65.
15. Snedecor S, Sudharshan L, Cappelleri J et al. Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. Pain Pract 2014; 14 (2): 167–84.
16. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167 (4): 465–71.
17. Maizels M, Mccarberg B. Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain. J Am Ac Fam Physicians 2005; 71; 3: 188–192.
18. Taylor C. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153 (Suppl. 1): S39–45.
19. Backonja M, Beydoun A, Edwards K et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6.
20. Rowbotham M, Harden N, Stacey B, Bernstein P. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42.
21. Hempenstall K, Nurmikko T, Johnson R et al. Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review. PLoS Med 2005; 2 (7): 164–9.
22. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. The Cochrane Database of Syst Rev 2005; 3. Art. No.: CD005452.
23. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16 (2 Suppl.): S67–72.
24. Morello C., Leckband S., Stoner C. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159 (16): 1931–7.
25. Dworkin R, O'Connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl.): S3–14.
26. Храмилин В.Н., Андреева В.Л., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16.
2. Head KA. Peripheral Neuropathy: Pathogenic Mechanisms and Alternative Therapies. Alternative Med Rev 2006; 11: 294–300.
3. Witzel I-I, Jelinek H, Khalaf K et al. Identifying Common Genetic Risk Factors of Diabetic Neuropathies. Front Endocrinol (Lausanne) 2015; 6: 88–93.
4. Jin HY, Baek HS, Park TS. Morphologic Changes in Autonomic Nerves in Diabetic Autonomic Neuropathy. Diabetes Metab J 2015; 39(6): 461–7.
5. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029–52.
6. Koo BK. Screening of autonomic neuropathy in patients with type 2 diabetes. Diabetes Metab J 2014; 38: 346–8.
7. Гурьева И.В., Левин О.С. Диабетическая полинейропатия. Consilium Medicum. 2014; 16 (4): 12–6. / Gur'eva I.V., Levin O.S. Diabeticheskaia polineiropatiia. Consilium Medicum. 2014; 16 (4): 12–6. [in Russian]
8. Karayannis G, Giamouzis G, Cokkinos D et al. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 2012; 10 (6): 747–65.
9. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne) 2014; 5: 205–10.
10. Cohena J, Estaciob R, Lundgrenc R et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108 (1–2): 7–8.
11. Sun L, Chen Y, Wang X et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol 2012; 84 (7): 961–73.
12. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
13. Mitkov M, Aleksandrova I, Orbetzova M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55 (1): 55–63.
14. Tesfaye S, Boulton A, Dickenson A. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36 (9): 2456–65.
15. Snedecor S, Sudharshan L, Cappelleri J et al. Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. Pain Pract 2014; 14 (2): 167–84.
16. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167 (4): 465–71.
17. Maizels M, Mccarberg B. Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain. J Am Ac Fam Physicians 2005; 71; 3: 188–192.
18. Taylor C. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153 (Suppl. 1): S39–45.
19. Backonja M, Beydoun A, Edwards K et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6.
20. Rowbotham M, Harden N, Stacey B, Bernstein P. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42.
21. Hempenstall K, Nurmikko T, Johnson R et al. Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review. PLoS Med 2005; 2 (7): 164–9.
22. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. The Cochrane Database of Syst Rev 2005; 3. Art. No.: CD005452.
23. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16 (2 Suppl.): S67–72.
24. Morello C., Leckband S., Stoner C. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159 (16): 1931–7.
25. Dworkin R, O'Connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl.): S3–14.
26. Храмилин В.Н., Андреева В.Л., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16.
________________________________________________
2. Head KA. Peripheral Neuropathy: Pathogenic Mechanisms and Alternative Therapies. Alternative Med Rev 2006; 11: 294–300.
3. Witzel I-I, Jelinek H, Khalaf K et al. Identifying Common Genetic Risk Factors of Diabetic Neuropathies. Front Endocrinol (Lausanne) 2015; 6: 88–93.
4. Jin HY, Baek HS, Park TS. Morphologic Changes in Autonomic Nerves in Diabetic Autonomic Neuropathy. Diabetes Metab J 2015; 39(6): 461–7.
5. Tremont-Lukats I, Megeff C, Backonja M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029–52.
6. Koo BK. Screening of autonomic neuropathy in patients with type 2 diabetes. Diabetes Metab J 2014; 38: 346–8.
7. Gur'eva I.V., Levin O.S. Diabeticheskaia polineiropatiia. Consilium Medicum. 2014; 16 (4): 12–6. [in Russian]
8. Karayannis G, Giamouzis G, Cokkinos D et al. Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 2012; 10 (6): 747–65.
9. Verrotti A, Prezioso G, Scattoni R, Chiarelli F. Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausanne) 2014; 5: 205–10.
10. Cohena J, Estaciob R, Lundgrenc R et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci 2003; 108 (1–2): 7–8.
11. Sun L, Chen Y, Wang X et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol 2012; 84 (7): 961–73.
12. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365–70.
13. Mitkov M, Aleksandrova I, Orbetzova M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55 (1): 55–63.
14. Tesfaye S, Boulton A, Dickenson A. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36 (9): 2456–65.
15. Snedecor S, Sudharshan L, Cappelleri J et al. Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. Pain Pract 2014; 14 (2): 167–84.
16. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167 (4): 465–71.
17. Maizels M, Mccarberg B. Antidepressants and Antiepileptic Drugs for Chronic Non-Cancer Pain. J Am Ac Fam Physicians 2005; 71; 3: 188–192.
18. Taylor C. Mechanisms of action of gabapentin. Rev Neurol (Paris) 1997; 153 (Suppl. 1): S39–45.
19. Backonja M, Beydoun A, Edwards K et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831–6.
20. Rowbotham M, Harden N, Stacey B, Bernstein P. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42.
21. Hempenstall K, Nurmikko T, Johnson R et al. Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review. PLoS Med 2005; 2 (7): 164–9.
22. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. The Cochrane Database of Syst Rev 2005; 3. Art. No.: CD005452.
23. Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000; 16 (2 Suppl.): S67–72.
24. Morello C., Leckband S., Stoner C. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159 (16): 1931–7.
25. Dworkin R, O'Connor A, Audette J et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl.): S3–14.
26. Храмилин В.Н., Андреева В.Л., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16.
Авторы
П.Р.Камчатнов*1, М.А.Евзельман2
1 ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБОУ ВПО Орловский государственный университет им. И.С.Тургенева. 302026, Россия, Орел, ул. Комсомольская, д. 95
*pavkam7@gmail.com
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 I.S.Turgenev Oryol State University. 302026, Russian Federation, Oryol, ul. Komsomol'skaia, d. 95
*pavkam7@gmail.com
1 ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
2 ФГБОУ ВПО Орловский государственный университет им. И.С.Тургенева. 302026, Россия, Орел, ул. Комсомольская, д. 95
*pavkam7@gmail.com
________________________________________________
1 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
2 I.S.Turgenev Oryol State University. 302026, Russian Federation, Oryol, ul. Komsomol'skaia, d. 95
*pavkam7@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.